Study aim: Evaluation of the effects of the aqueous extract of Alhagi papilionaceae or petals Saffron petal and mountain tea herbs on the clinical and paraclinical symptoms of COVID-19 patients Design: Clinical trial with control group, double blind, randomized, phase 2on 40 patients. With the help of a statistician as well as the use of appropriate software (probably SAS Version 9.2 (SAS institute Inc., Cary, NC)) Settings and conduct: Blood samples will be collected from patients. Liver and kidney function are assessed in patients. Includes assessment of length of hospital stay, mortality rate, and pulmonary infiltration rate based on X-ray or CT scan of the lungs. It will be prescribed to patients by a doctor and will be performed in Ali Ibn Abitaleb Hospital in Rafsanjan Participants/Inclusion and exclusion criteria: Inclusion criteria in this study included all patients in whom Covid 19 infection was confirmed. Exclusion criteria included patients with other infections or diseases such as influenza, pulmonary insufficiency, ARDS pneumonia and other cold symptoms. Intervention groups: The intervention group includes patients with COVID-19 who receive herbal compounds (including aqueous extract of Ador-Cancer, saffron petals and mountain tea). The control group includes patients with COVID-19 who receive placebo Main outcome variables: Duration of hospitalization of patients with Covid-19 Mortality rate of patients with Covid-19 Pulmonary infiltration rate in patients with Covid-19